Verastem (VSTM) hosts its annual research and development day. Highlights: VSTM says it plans to have "three candidates in six clinical trials ongoing in parallel by the end of 2013"; Phase 1 portion of Phase 1/1b VS-6063 study is complete; "a significant decrease in the CA-125 biomarker in several patients" was observed; treatment is well tolerated in combination with paclitaxel, opening the door for exploring "this combination in a wide range of cancers."
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Jan 13, 2015)
at Nasdaq.com (Dec 29, 2014)
at MarketWatch.com (Feb 2, 2012)
at MarketWatch.com (Jan 30, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs